PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Phenotype | C0036341|schizophrenia |
| Sentences | 21 |
| PubMedID- 23599376 | Conversely, it is possible that in addition to the under-recognition and under-recording of cardiovascular disease in patients with schizophrenia, some of the prevalence rates for other physical-health comorbidities may be underestimated. |
| PubMedID- 20079332 | Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. |
| PubMedID- 25309466 | Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. |
| PubMedID- 24143102 | The statistical power for e/a was calculated as 0.899. these results, as well, may indicate existing diastolic function and risk for cardiovascular disease; therefore, patients with schizophrenia should be followed-up closely. |
| PubMedID- 23982303 | The overlap in genetic risk is important since there is significant mortality from cardiovascular disease in patients with schizophrenia suggesting the need to better monitor cardiovascular disease in these patients (gegenava and kavtaradze, 2006; laursen et al., 2012). |
| PubMedID- 24710015 | Most antipsychotic medications are associated with an increased risk for metabolic disturbances, such as weight gain, obesity, diabetes, hyperlipidemia, which ultimately contribute to an increased risk for cardiovascular disease in patients with schizophrenia [25]. |
| PubMedID- 26001844 | Protocol for change: a randomized clinical trial assessing lifestyle coaching plus care coordination versus care coordination alone versus treatment as usual to reduce risks of cardiovascular disease in adults with schizophrenia and abdominal obesity. |
| PubMedID- 25542737 | schizophrenia is associated with increased cardiovascular disease morbidity and mortality. |
| PubMedID- 24751159 | People with serious mental illness such as schizophrenia have higher levels of cardiovascular disease [6,7], metabolic disease [8], diabetes [9,10], and respiratory illness [11,12]. |
| PubMedID- 26360288 | These patients have a 20-year shorter lifespan than peers without schizophrenia, mainly due to premature cardiovascular disease, suicide, and cancer. |
| PubMedID- 25884721 | Based on the diagnosis reported by gps, the prevalence of hypertension and cardiovascular diseases among patients with schizophrenia is similar to population means. |
| PubMedID- 21300937 | Context: the increased mortality associated with schizophrenia is largely due to cardiovascular disease. |
| PubMedID- 24143103 | Considering the increased rates of cardiovascular diseases in patients with schizophrenia compared with the normal population, these findings are noteworthy. |
| PubMedID- 21664905 | An association is established between schizophrenia and the development of metabolic alterations including cardiovascular diseases, type 2 diabetes and obesity. |
| PubMedID- 23225174 | In order to reduce the risk of cardiovascular disease in patients with schizophrenia receiving antipsychotic agents, obtaining fasting lipid measurements at regular intervals is needed. |
| PubMedID- 26528652 | Objective: metabolic and cardiovascular diseases in patients with schizophrenia have gained a lot of interest in recent years. |
| PubMedID- 20923921 | Although the highest number of excess deaths in schizophrenia is associated with cardiovascular disease, people with schizophrenia have low rates of surgical interventions such as stenting and bypass grafting (druss et al., 2000; kisely et al., 2007; lawrence et al., 2003; laursen et al., 2009). |
| PubMedID- 24359325 | A large population-based danish study found that the recording of cardiovascular disease in individuals with bipolar disorder, schizophrenia and schizoaffective disorder was incomplete, and management insufficiently intensive [17]. |
| PubMedID- 24365456 | It has been proposed that smoking cessation would produce a 75% reduction in high/very high risk of cardiovascular disease in people with schizophrenia (bobes et al.2010). |
| PubMedID- 21964485 | C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. |
| PubMedID- 23515714 | Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in german psychiatric hospitals: results of the pharmacoepidemiologic cats study. |
Page: 1